Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

—For medical teams tasked with caring for patients with diffuse large B-cell lymphoma, progression or relapse that involves the central nervous system can be extremely challenging and potentially life ...

Genmab plans to present full results at an upcoming medical meeting.

The FDA approved Epkinly in combination with other standard lymphoma drugs, rituximab + lenalidomide, for relapsed or ...

Recombinant Hirudin (rH) inhibited the polarization of M2-type macrophages and protease-activated receptor-1 (PAR-1) in diffuse large B-cell lymphoma (DLBCL). A study of 32 clinical samples from ...

Reflecting on a patient experience during a fellowship in 2015, Suchitra Sundaram, MD, notes how the standard treatment for stage IV ABC-subtype diffuse large B-cell lymphoma (DLBCL) was R-CHOP ...

The median age at diagnosis was 47 years (range, 14-89). Male:female ratio was 2.5:1. Majority of the patients (69.3%) were treated in limited-resource settings. Computed tomography was used as a ...

Suchitra Sundaram, MD, emphasizes the significant disparities in the treatment and outcomes of patients with diffuse large B-cell lymphoma (DLBCL), which arise from a complex interaction of factors ...

BOSTON--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel ...

A case study details the cytological and histological features of fibrin-assisted diffuse large B-cell lymphoma in a patient with no clinical symptoms, highlighting the diagnostic challenges of this ...